The article identifies three dividend stocks with strong fundamentals and resilient business models that are likely to continue raising payouts through economic downturns: WD-40 Company with 40 years of uninterrupted dividends backed by an iconic product with minimal competition, Energizer Holdings yielding 5.9% with essential consumer products, and Haleon with a conservative payout policy and health brands used by over a billion consumers worldwide.

In a comparison of two Consumer Products - Discretionary stocks, Lifetime Brands (LCUT) emerges as the better value investment option compared to Haleon PLC Sponsored ADR (HLN). LCUT holds a Zacks Rank #1 (Strong Buy) with superior valuation metrics including a forward P/E of 4.05 versus HLN's 16.23, a PEG ratio of 0.29 versus 2.05, and a P/B ratio of 0.88 versus 1.84. LCUT also earned a Value grade of A compared to HLN's C grade.

The global dietary supplements market is projected to grow from USD 151.82 billion in 2026 to USD 187.22 billion by 2031 at a CAGR of 4.28%. Growth is driven by preventive healthcare adoption, aging populations, and shifting consumer preferences toward convenient formats like gummies and liquids. Asia-Pacific leads market share, while clean-label and personalized nutrition solutions are reshaping the industry.

Pfizer has sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the second half.

Haleon, the maker of Sensodyne toothpaste, reported a 0.6% decline in revenue for 2024 but expects 4-6% organic revenue growth in 2025, with stronger performance in the second half of the year. The company faces foreign exchange headwinds that may impact revenue and profit.

Dr Reddy's Laboratories reported a 16% increase in Q3 revenue, driven by its newly acquired Nicotine Replacement Therapy (NRT) portfolio and growth in emerging markets. The company's global generics revenue grew 17% year-over-year, with 7% growth excluding NRT contributions.

Pfizer is expected to provide its 2025 financial guidance on Tuesday. Goldman Sachs projects Pfizer's 2025 EPS to be higher than consensus, driven by strong Paxlovid sales, though Vyndaqel forecast misses consensus.

The global pediatric oral care market is expected to grow significantly due to rising awareness of early oral hygiene and increasing prevalence of dental issues in children. Demand for specialized products, including toothbrushes, toothpaste, and dental floss, is driving market expansion.

Pfizer's COVID-19 products continue to generate significant cash flow, helping bolster the company's dividend. Pfizer's ability to monetize assets and its new product pipeline also contribute to the safety of its ultra-high-yield dividend.

Pfizer's stock has fallen over 60% since its peak during the pandemic, but the company is showing signs of recovery with revenue growth and a robust drug pipeline. The stock is trading at a value with a high dividend yield, making it an attractive investment opportunity.

The global OTC drug and dietary supplement market is expected to grow from $310.96 billion in 2023 to $632.1 billion in 2033, driven by factors like rising health consciousness, increasing demand for dietary supplements, and expansion of the e-commerce industry. The report highlights opportunities in the vitamin and dietary supplements, tablets, and pharmacies segments, as well as trends like new OTC options for opioid overdose reversal and innovation in women's health pharmaceuticals.

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding from 22.6% to 15%. Haleon, known for products like Sensodyne toothpaste and Panadol painkillers, saw its shares drop 1.2% on the news.